Inhaled nitric oxide for the treatment of preterm infants with respiratory distress syndrome.

Article review
Name
Institution
Abstract
Severe lung disease is a prolonged critical complication of the pulmonary that often affects the infants. The condition has a relationship with pulmonary hypertension and postnatal abnormalities as well as neovascularization. On top of the case of growth impairment, the infants that suffer from severe or chronic lung diseases and related complications may succumb to long-lasting cardiopulmonary function as well as an increment in risks towards infections. Other effects include sharp increment in the risks of exposure to the abnormal neurologic development. Nitric oxide leads to the attenuation of the pulmonary vascular disease, inflammation cases and the incidences of pulmonary hypertension among the newborns that have injured lungs. In this study, the hypothesis put across was that the application of the inhaled nitric acid has the likelihood of resulting into decrement in the incidences of chronic lung disease and even early deaths among the infants. Most of the affected infants are those that suffer from respiratory disease syndrome who were under mechanical ventilation.
Review of the article
In their view, Dani & Bertini, (2008) reiterated that an inhaled nitric oxide has the likelihood of causing improvement in the process of oxygenation within the preterm neonates that suffer from the respiratory distress syndrome and decrement in the risks linked with bronchopulmonary dysplasia. Based on the studies that tackle on the iNO effects on the infants who are still preterm, the results that have been got from iRDS is has been contradicting in nature.

Dani & Bertini, (2008) in most parts of this article present a report of the methodological features and the observational effects arising from iNO among the preterm infants. Added to the same, they also present a discussion of the age of the infants, the duration for taking the iNO therapy and the possible impacts or the effects of the same on the neurodevelopment. The same discussion also covers on the association with those properties due to surfactants and the urge in the identification of patients that are at higher chances of showing responses to the therapy. In this regard, this article warns against the instance of the widespread nature of the application of iNO among the preterm infants who also happen to iRDS. As at present, it seems somehow that the premature show some certain recommendations about the prescriptions for iNO therapy among this category of patients.
According to the research conducted by Dani & Bertini, (2008) in this study on inhaled nitric oxide for the treatment of preterm infants with respiratory distress syndrome, iNO therapy has a chance towards being one of the treatment options for the preterm patients what have iRDS. The reason is that it leads to the improvement in the process of oxygenation during the acute stages. At the same time, the therapy causes the decrement in the BPD occurrence, pulmonary vasculogenesis regulation and also serving the role of an anti-inflammatory as well as an antioxidant agent. However, the study noted that RCTs had not been approved following these consumptions and at the same also provides those results that seem so conflicting simply because of their designs that are unique. The instance here indeed becomes a great limitation to the value of the meta-evaluation of the cumulated idea that emerged from varied RCTs. Regardless of the same, the ever witnessed tests appear to give a suggestion of iNO therapy being of use in the decrement of the death occurrences and the BPD among the preterm infants that suffer from mild or moderate iRDS. In this case, it about those patients that are not that aged and also during the incidences that take longer times for medication.
Finally, in responses to some of the trials carried out during the research work in this study, they revealed that iNO therapy is indeed very safe and does not in any lead to the increment in the severe rates of the ICH and PVL. On top of this, some latest studies on the same as carried out by Dani & Bertini, (2008) in the course of this study also show that iNO may have some effects of protection on the preterm infants’ neurodevelopment. On the other hand, in undertaking the assessment of the outcomes from the research done during this study, Dani & Bertini, (2008) stress that during the completion of the evaluation of data at posthoc subgroup; there are some confusing conclusions that may be reached. The instance here may take place in situations that become hard in finding the exact explanation expected from one sect of patients in showing better responses when compared to the other.
Reference
Dani, C., & Bertini, G. (2008). Inhaled nitric oxide for the treatment of preterm infants withrespiratory distress syndrome By Neonatology, 94(2), 87-95.